Depression Events Associated with Proton-Pump Inhibitors in Postmarketing Drug Surveillance Data

Depression Events Associated with Proton-Pump Inhibitors in Postmarketing Drug Surveillance Data

Proton-pump inhibitors, PPIs, are widely prescribed and are available over the counter for prolonged reduction of stomach acid production and related disorders. PPIs irreversibly inhibit the hydrogen/potassium ATPase in gastric parietal cells. Recent retrospective studies have described an associati...

Full description

Bibliographic Details
Main Authors:	Tigran Makunts, Haroutyun Joulfayan, Kenneth Ta, Ruben Abagyan
Format:	Article
Language:	English
Published:	MDPI AG 2023-08-01
Series:	Pharmacoepidemiology
Subjects:	proton-pump inhibitors PPIs FAERS depression drug safety adverse events
Online Access:	https://www.mdpi.com/2813-0618/2/3/23

Similar Items

Anti-TNF-α therapy induced psoriasis in rheumatoid arthritis patients according to FDA postmarketing surveillance data
by: Haroutyun Joulfayan, et al.
Published: (2023-06-01)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2023-05-01)

In-hospital gastric protection with proton pump inhibitors: adverse effects beyond (over)utilization?
by: Paolo Montanari
Published: (2013-04-01)

Proton-pump inhibitors
by: Vasudevan G. Naidoo
Published: (2015-05-01)

Proton Pump Inhibitors Use and Risk of Preeclampsia: A Meta-Analysis
by: Salman Hussain, et al.
Published: (2022-08-01)

Proton pump inhibitors induce hemolytic anemia
by: Asayil Nasser Al-Nasser, et al.
Published: (2019-01-01)

Influence of generics in prescribing dynamics of proton pump inhibitors in general practice
by: Simona Cammarota, et al.
Published: (2009-03-01)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
by: Rui Xiong, et al.
Published: (2023-09-01)

Pharmacovigilance Analysis of Serious Adverse Events Reported for Biologic Response Modifiers Used as Prophylaxis against Transplant Rejection: a Real-World Postmarketing Experience from the US FDA Adverse Event Reporting System (FAERS)
by: A. K. Ali
Published: (2013-04-01)

Evaluation of Proton Pump Inhibitors Prescribing Among Hospitalized Patients: A Cross-Sectional Study
by: Abukhalil AD, et al.
Published: (2023-01-01)

Concomitant medications associated with ischemic, hypertensive, and arrhythmic events in MDMA users in FDA adverse event reporting system
by: Tigran Makunts, et al.
Published: (2023-05-01)

Use of Clopidogrel and Proton Pump Inhibitors Alone or in Combinations in Persons with Diabetes in Denmark; Potential for CYP2C19 Genotype-Guided Drug Therapy
by: Niels Westergaard, et al.
Published: (2021-02-01)

'Lemonade Legs': Why do Some Patients Get Profound Hypomagnesaemia on Proton-Pump Inhibitors?
by: Nathan S. S. Atkinson, et al.
Published: (2015-07-01)

Gastro-oesophageal reflux: an overview of the pharmacotherapeutic treatment options
by: L Malan, et al.
Published: (2017-07-01)

Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database
by: Tigran Makunts, et al.
Published: (2022-01-01)

Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study
by: Yun Li, et al.
Published: (2024-03-01)

Critical Hypomagnesemia and Seizure Induced by Chronic Use of Proton Pump Inhibitors (PPIs)
by: Gheith Yousif
Published: (2019-06-01)

Retrospective analysis of adverse events with spironolactone in females reported to the United States Food and Drug Administration
by: Yu Wang, BA, et al.
Published: (2020-09-01)

Proton pump inhibitors overuse: only inappropriate prescriptions or further iatrogenic damage?
by: Mario Visconti
Published: (2015-09-01)

The effects of proton pump inhibitors on the development of post-stenting major adverse cardiovascular events in patients with acute coronary syndrome
by: Yigit Oguz Unal, et al.
Published: (2023-06-01)

Proton Pump Inhibitors: Are They a Real Threat to the Patient?
by: Sofia Xavier, et al.
Published: (2018-02-01)

Proton Pump Inhibitors Enhance the Antitumor Effect of Chemotherapy for Esophageal Squamous Cell Carcinoma
by: Shinya Matsumura, et al.
Published: (2022-05-01)

Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System
by: Yang Bai, et al.
Published: (2023-09-01)

Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study
by: Tengfei Yuan, et al.
Published: (2023-11-01)

Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)
by: Lin Zhang, et al.
Published: (2023-11-01)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Yamin Shu, et al.
Published: (2022-06-01)

A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system
by: Bin Zhao, et al.
Published: (2024-03-01)

A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system
by: Mingdi Liu, et al.
Published: (2024-01-01)

PPI efficacy in the reduction of variceal bleeding incidence and mortality, a meta-analysis
by: Sheref A. Elseidy, et al.
Published: (2022-09-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib
by: Yu Lin, et al.
Published: (2024-03-01)

Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database
by: Junwei Wang, et al.
Published: (2024-03-01)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2022-10-01)

How can proton pump inhibitors damage central and peripheral nervous systems?
by: Tigran Makunts, et al.
Published: (2020-01-01)

Cardiovascular Adverse Events Associated with Monoclonal Antibody Products in Patients with COVID-19
by: Jingrui Zou, et al.
Published: (2022-11-01)

Proton pump inhibitors overuse - consequences among patients
by: Patrycja Kmiotek, et al.
Published: (2019-08-01)

Proton pump inhibitors overuse - consequences among patients
by: Patrycja Kmiotek, et al.
Published: (2019-08-01)

Gastro-oesophageal reflux: An overview of the cost-effectiveness of pharmacotherapeutic treatment options
by: Gustav Schellack, et al.
Published: (2016-03-01)

NSAIDs and PPIs - review of new reports
by: Jakub Klas, et al.
Published: (2021-09-01)

Modified PPIs (a search for the better)
by: Hussein Abdel-Hamid
Published: (2016-01-01)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
by: Haoning Guo, et al.
Published: (2022-04-01)